A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The primary purpose of this study is to evaluate the effect of a single 84-milligram (mg) dose of intranasal esketamine compared to placebo, on next day driving performance and repeated administration of 84 mg intranasal esketamine on same-day driving performance as assessed by the mean difference of standard deviation of lateral position (SDLP) from an on-road driving test.
Epistemonikos ID: ade29ccb71b7e7c3225fa3fe01fdf04f8b4d2e58
First added on: May 17, 2024